Salesforce (CRM) Offering Possible 36.99% Return Over the Next 21 Calendar Days

Salesforce's most recent trend suggests a bullish bias. One trading opportunity on Salesforce is a Bull Put Spread using a strike $220.00 short put and a strike $215.00 long put offers a potential 36.99% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $220.00 by expiration. The full premium credit of $1.35 would be kept by the premium seller. The risk of $3.65 would be incurred if the stock dropped below the $215.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Salesforce is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Salesforce is bullish.

The RSI indicator is at 61.58 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Salesforce

Salesforce.com (CRM) Stock Moves -0.65%: What You Should Know
Wed, 27 Jan 2021 22:45:10 +0000
Salesforce.com (CRM) closed at $224.78 in the latest trading session, marking a -0.65% move from the prior day.

Salesforce Announces Vaccine Cloud To Help Organize Rollout
Wed, 27 Jan 2021 21:12:28 +0000
Salesforce.com Inc. (NYSE: CRM) will release a Vaccine Cloud to help the Biden administration meet its target of vaccinating 100 million people in 100 days. What Happened: On Wednesday, Salesforce said it would launch a new software program called Vaccine Cloud to help governments and health care providers manage and maintain records related to COVID-19 vaccinations. The service will also help agencies manage their vaccine inventory and plan for doses based on what is needed. Bret Taylor, the president and chief operating officer of Salesforce, said, “The biggest challenge the world faces right now is orchestrating the distribution of millions of vaccine doses. Technology can play a critical role.” Why It Matters: The Vaccine Cloud is the next step in Salesforce’s initiative to help governments smooth out the issues around the quick and orderly inoculation of billions of people around the world. On Jan. 13, Salesforce announced it was working with Microsoft Corporation (NASDAQ: MSFT) and Oracle Corporation (NYSE: ORCL), as well as not-for-profit Mayo Clinic, in a coalition known as the Vaccination Credential Initiative to offer the public encrypted digital copies of their vaccination records as proof of immunity. The digital copies, or “digital passports,” would replace the paper booklets currently used to keep track of inoculations and could be stored in digital wallets such as Apple Wallet or Google Pay. What’s Next: Salesforce said it hopes the Vaccine Cloud will help governments, agencies and individuals plan vaccinations and keep track of health records. The Vaccine Cloud will also allow individuals to easily show proof of vaccinations if asked. (Photo: Steven Cornfield on Unsplash) See more from BenzingaClick here for options trades from Benzinga5 Microsoft Analysts Break Down Q2 Beat As More Organizations Shift To CloudMolson Coors Partners With CKBG On Sugar-Free Alcoholic Beverages© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Microsoft looks unstoppable: analyst
Wed, 27 Jan 2021 18:21:46 +0000
Microsoft continues to do what it does — blow minds on Wall Street.

Salesforce unveils Vaccine Cloud to manage COVID-19 records
Wed, 27 Jan 2021 13:03:47 +0000
Salesforce Inc said on Wednesday it is launching Vaccine Cloud to help governments and healthcare providers globally maintain and manage digital records of COVID-19 vaccinations. The new product, which will help people register and schedule for their vaccine shots, would also help government agencies and public health providers secure enough vaccine doses and monitor patient outcomes, Salesforce said.

Influencers with Andy Serwer: Mubarak Muyika
Wed, 27 Jan 2021 12:00:00 +0000
In this episode of Influencers, Andy is joined by Mubarak Muyika, founder and president of Zagace, as they discuss Mubarak's entrepreneurial journey, why he turned down a scholarship from Harvard University, and what he admires about billionaires Warren Buffett and Bill Gates.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.